SMA 50 spoločnosti 4SC AG

Aká je hodnota metriky SMA 50 spoločnosti 4SC AG?

Hodnota metriky SMA 50 spoločnosti 4SC AG je €3 +1.01%

Aká je definícia metriky SMA 50?



SMA 50 (Simple Moving Average 50) je priemerná cena akcie za posledných 50 dní vypočítaná ako nevážený priemer z predchádzajúcich 50 záverečných cien.

Simple moving average of 50 days for a stock is an unweighted moving average over the past 50 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.

Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.

SMA 50 spoločností v sektore Health Care sektor na XETRA v porovnaní so spoločnosťou 4SC AG

Čomu sa venuje spoločnosť 4SC AG?

4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.

Firmy s metrikou sma 50 podobnou spoločnosti 4SC AG